Saxenda plus intermittent fasting: what the combo actually does

What did @reneedekock actually say?

The creator says they are "starting a new Saxenda pen," testing a dose, and that they "quickly get satisfied." That is the sum of the content here. There is no dosing advice, no dramatic weight loss claim, just a personal observation about early satiety after starting or resuming liraglutide. The transcript is sparse, but the core claim is clear: Saxenda produces fast-onset satiety for this user.

Worth noting: the transcript appears to have transcription artifacts, with "SAC Sender Pad" clearly meaning "Saxenda pen" and "Testing it. 10" likely referring to a pen dial or dose step. Nothing in the video crosses into prescriptive territory based on what was said.

Does the science back this up?

Yes, with some nuance. Liraglutide (the active ingredient in Saxenda) does produce satiety, and that effect can begin relatively quickly after injection, but "quickly" depends on what you mean.

Liraglutide is a GLP-1 receptor agonist. GLP-1 receptors are found in the gut and in the brain, particularly the hypothalamus and brainstem areas that regulate appetite. When liraglutide activates those receptors, it slows gastric emptying and reduces appetite signaling. Van Can et al. (2014, International Journal of Obesity) showed that a single dose of liraglutide reduced energy intake at a meal served 5 hours post-injection, suggesting appetite suppression that operates on a timescale of hours, not minutes.

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) confirmed that patients on liraglutide 3.0 mg reported significantly reduced hunger and increased satiety versus placebo over 56 weeks. So the satiety effect is real and well-documented.

What did they get wrong (or right)?

They got the basic mechanism right by lived experience. Saxenda does produce satiety, and many users report noticing it early in treatment. Credit where it is due.

The potential issue is the phrase "quickly get satisfied." If viewers interpret this as meaning Saxenda produces near-immediate satiety within minutes of injection, that is not accurate pharmacology. Liraglutide has a half-life of approximately 13 hours and works systemically, not like a drug that hits in 20 minutes. The satiety people feel is a sustained, hours-long effect on appetite regulation, not a rapid-onset response tied to the injection moment itself.

There is also a common conflation in GLP-1 content between feeling less hungry and losing weight. Reduced appetite is a mechanism, not an outcome guarantee. Wilding et al. (2021, NEJM) on semaglutide showed that even with strong appetite suppression, individual weight loss results varied considerably. The same logic applies to liraglutide.

• Saxenda does reduce appetite. That part is accurate.
• The speed and mechanism of that satiety is more complex than "quickly" implies.
• No dosing guidance was given, which is appropriate for a personal testimonial format.

What should you actually know?

If you are considering Saxenda, the satiety effect is a real and meaningful part of how it works, but it is not the whole story. Liraglutide requires dose titration over several weeks to minimize nausea and GI side effects. Starting at a full therapeutic dose is not how this medication is used, and the titration schedule exists for good reason.

The SCALE trials showed average weight loss of around 8 percent of body weight over 56 weeks at the 3.0 mg dose, which is meaningful but not transformative for everyone. About one-third of participants in Pi-Sunyer et al. (2015) lost 10 percent or more of body weight, meaning a substantial portion did not. Satiety alone does not determine outcomes.

Saxenda is also not interchangeable with compounded liraglutide products. Regulatory status, formulation, and quality standards differ. If you are prescribed liraglutide, the specific product matters and should be discussed with a licensed prescriber.

The bottom line

This video is a low-stakes personal update, not a medical claim factory. The core observation, that Saxenda produces satiety, is supported by real evidence. The framing of "quickly" is imprecise but not dangerous. What this video does not do is explain the titration process, the variability in outcomes, or the difference between appetite suppression and guaranteed weight loss. That context gap is where viewers should be cautious, not because the creator said something wrong, but because personal testimonials about GLP-1 medications routinely leave out the parts that complicate the story.